These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 18675682)

  • 1. Basal insulin glargine vs prandial insulin lispro in type 2 diabetes.
    Roden M
    Lancet; 2008 Aug; 372(9636):371; author reply 372. PubMed ID: 18675682
    [No Abstract]   [Full Text] [Related]  

  • 2. Basal insulin glargine vs prandial insulin lispro in type 2 diabetes.
    Arnolds S; Rave K
    Lancet; 2008 Aug; 372(9636):370-1; author reply 372. PubMed ID: 18675680
    [No Abstract]   [Full Text] [Related]  

  • 3. Basal insulin glargine vs prandial insulin lispro in type 2 diabetes.
    Oliveira JH; Kazda C; Simpson A; Jackson JA; Heine RJ
    Lancet; 2008 Aug; 372(9636):371-2; author reply 372. PubMed ID: 18675683
    [No Abstract]   [Full Text] [Related]  

  • 4. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy.
    Kazda C; Hülstrunk H; Helsberg K; Langer F; Forst T; Hanefeld M
    J Diabetes Complications; 2006; 20(3):145-52. PubMed ID: 16632233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of prandial plus basal vs basal insulin on glycemic variability in type 2 diabetic patients.
    Hirsch IB; Yuan H; Campaigne BN; Tan MH
    Endocr Pract; 2009; 15(4):343-8. PubMed ID: 19454394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.
    Bretzel RG; Nuber U; Landgraf W; Owens DR; Bradley C; Linn T
    Lancet; 2008 Mar; 371(9618):1073-84. PubMed ID: 18374840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin glargine clinical trials.
    White JR
    Clin Ther; 2004 Jul; 26(7):1179-81; discussion 1182-3. PubMed ID: 15336483
    [No Abstract]   [Full Text] [Related]  

  • 8. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
    Ilag LL; Kerr L; Malone JK; Tan MH
    Clin Ther; 2007 Jun; 29(6 Pt 1):1254-70. PubMed ID: 18036388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ; Scism-Bacon JL; Zagar AJ
    Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.
    Rosenstock J; Fonseca VA; Gross JL; Ratner RE; Ahrén B; Chow FC; Yang F; Miller D; Johnson SL; Stewart MW; Leiter LA;
    Diabetes Care; 2014 Aug; 37(8):2317-25. PubMed ID: 24898300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial.
    Tinahones FJ; Gross JL; Onaca A; Cleall S; Rodríguez A
    Diabetes Obes Metab; 2014 Oct; 16(10):963-70. PubMed ID: 24725616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy.
    Malone JK; Kerr LF; Campaigne BN; Sachson RA; Holcombe JH;
    Clin Ther; 2004 Dec; 26(12):2034-44. PubMed ID: 15823767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes.
    Malone JK; Bai S; Campaigne BN; Reviriego J; Augendre-Ferrante B
    Diabet Med; 2005 Apr; 22(4):374-81. PubMed ID: 15787659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial.
    Rosenstock J; Nino A; Soffer J; Erskine L; Acusta A; Dole J; Carr MC; Mallory J; Home P
    Diabetes Care; 2020 Oct; 43(10):2509-2518. PubMed ID: 32694215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initiating insulin therapy in elderly patients with Type 2 diabetes: efficacy and safety of lispro mix 25 vs. basal insulin combined with oral glucose-lowering agents.
    Wolffenbuttel BH; Klaff LJ; Bhushan R; Fahrbach JL; Jiang H; Martin S
    Diabet Med; 2009 Nov; 26(11):1147-55. PubMed ID: 19929994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Starting insulin therapy in type 2 diabetes: lesson 1.
    McCall AL
    Curr Diab Rep; 2005 Oct; 5(5):325-6. PubMed ID: 16188164
    [No Abstract]   [Full Text] [Related]  

  • 17. [Start of insulin therapy. How to ensure patient compliance?].
    MMW Fortschr Med; 2006 Aug; 148(35-36):12-3. PubMed ID: 16995354
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: trial comparing insulin detemir with insulin glargine.
    Swinnen S; Holleman F
    Clin Ther; 2009 May; 31(5):1124-5; author reply 1125-6. PubMed ID: 19539113
    [No Abstract]   [Full Text] [Related]  

  • 19. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
    Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
    Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct pharmacodynamics of insulin glargine and insulin detemir: crossover comparison in Type 1 and Type 2 diabetic patients on basal-bolus regimen.
    Kato T; Tokubuchi I; Muraishi K; Sato S; Kato T; Hara K; Tanaka K; Kaku H; Tajiri Y; Yamada K
    Diabetes Res Clin Pract; 2010 Dec; 90(3):e64-6. PubMed ID: 20850885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.